Vijay Kedia buys 9 lakh shares of SME inventory Mahamaya Lifesciences in Rs 12.5 crore block deal
Kedia bought the shares through his funding firm Kedia Securities Personal Ltd at a 2.8% low cost from the Monday closing value of Rs 144.05 per share.
Listed on November 18, 2025, Mahamaya Lifesciences shares hit their all-time excessive of Rs 161.70 on the BSE, immediately.
The inventory additionally witnessed one other block deal the place, Almondz International Securities Restricted bought 1.51 lakh shares at a value of Rs 143.64 per share.
Mahamaya Lifesciences is a producer and exporter of pesticide formulations and crop safety merchandise which is listed on the BSE SME platform.
The inventory had a lackluster itemizing at Rs 116 a share towards the problem value of Rs 114. However the inventory has prolonged its lead since making its market debut. It’s now up 42% over the IPO value.
Additionally Learn: Ola Electrical bulk deal: Promoter Bhavish Aggarwal sells 2.6 crore shares price Rs 92 croreThe Rs 70.44 crore IPO consisted of a recent situation price Rs 64.28 crore and a suggestion on the market of Rs 6.16 crore.
The IPO was subscribed 1.63 instances general, led by robust NII participation at 3.63 instances, whereas the retail class ended at 1.02 instances—simply above full subscription. QIBs bid 1.19 instances, reflecting a measured institutional stance. The difficulty’s excessive minimal funding dimension of Rs 2,73,600 for retail traders additionally meant restricted participation from small candidates.
Mahamaya Lifesciences manufactures pesticide formulations, technical-grade molecules and branded agri-inputs. It provides bulk merchandise to home agrochemical corporations and several other multinational companies.
The corporate additionally has a worldwide footprint, with product registrations and gross sales in international locations together with Egypt, Ethiopia, Jordan, the UAE and Turkey. Its product portfolio spans key formulations comparable to Acetamiprid, Emamectin Benzoate, Imidacloprid, Paraquat Dichloride and a number of branded plant-health merchandise.
The corporate posted robust progress in FY25, with income rising 64% to Rs 267.17 crore, whereas PAT grew 148% to Rs 12.94 crore. EBITDA elevated to Rs 24.64 crore, and web price practically doubled to Rs 49.42 crore.
IPO proceeds might be used for tools purchases, establishing a brand new technical manufacturing plant, warehouse building, working-capital wants, and normal company functions.
Additionally Learn: Usha Martin block deal: Promoter entity sells stake price Rs 99 crore. Morgan Stanley amongst consumers
(Disclaimer: The suggestions, strategies, views, and opinions given by the specialists are their very own. These don’t symbolize the views of The Financial Instances.)
